Zheng Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11368828/publications.pdf

Version: 2024-02-01

567281 888059 1,378 17 15 17 h-index citations g-index papers 17 17 17 1714 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake. Science, 2007, 317, 1390-1393.	12.6	317
2	Antidepressant specificity of serotonin transporter suggested by three LeuT–SSRI structures. Nature Structural and Molecular Biology, 2009, 16, 652-657.	8.2	239
3	Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP–TEAD Protein–Protein Interaction. ACS Medicinal Chemistry Letters, 2014, 5, 993-998.	2.8	130
4	Targeting Hippo pathway by specific interruption of YAPâ€TEAD interaction using cyclic YAPâ€like peptides. FASEB Journal, 2015, 29, 724-732.	0.5	115
5	Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms. Scientific Reports, 2017, 7, 42374.	3.3	103
6	Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling. Cell Reports, 2020, 31, 107809.	6.4	88
7	Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 7651-7666.	6.4	59
8	Dipolar Coupling between Nitroxide Spin Labels: The Development and Application of a Tether-in-a-Cone Model. Biophysical Journal, 2006, 90, 340-356.	0.5	58
9	Solution Structure of the Cytoplasmic Domain of Erythrocyte Membrane Band 3 Determined by Site-Directed Spin Labelingâ€. Biochemistry, 2005, 44, 15115-15128.	2.5	56
10	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 802-806.	2.8	54
11	Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 3352-3371.	6.4	46
12	Determination of Structural Models of the Complex between the Cytoplasmic Domain of Erythrocyte Band 3 and Ankyrin-R Repeats 13–24. Journal of Biological Chemistry, 2011, 286, 20746-20757.	3.4	30
13	Identification of New ATG4B Inhibitors Based on a Novel High-Throughput Screening Platform. SLAS Discovery, 2017, 22, 338-347.	2.7	28
14	Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator. Hepatology, 2019, 70, 11-24.	7.3	24
15	Structure of the Cytoplasmic Domain of Erythrocyte Band 3 Hereditary Spherocytosis Variant P327R: Band 3 Tuscaloosa. Biochemistry, 2007, 46, 10248-10257.	2.5	17
16	Automated Structure Refinement for a Protein Heterodimer Complex Using Limited EPR Spectroscopic Data and a Rigid-Body Docking Algorithm: A Three-Dimensional Model for an Ankyrin-CDB3 Complex. Journal of Physical Chemistry B, 2014, 118, 4717-4726.	2.6	8
17	A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles. Journal of Medicinal Chemistry, 2019, 62, 10352-10361.	6.4	6